CYTK earnings analysis
What we found in CYTK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cytokinetics reported Q1 2026 revenue of $19.4 million, significantly exceeding estimates of $8.5 million, while EPS of -$1.67 fell short of estimated -$1.65. The company is experiencing strong early demand for its approved product, MYQORZO, which commenced commercial sales in the quarter. SG&A expenses surged as it ramped up marketing efforts following the launch, alongside a continued high R&D expenditure.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeded Estimates
- Q1 2026 revenue reached $19.4 million, exceeding estimates of $8.5 million.
- Positive Net Product Revenue
- The company recorded $4.8 million in net product revenue from the commercial sales of MYQORZO.
- Strong Collaboration Revenue Growth
- Collaboration revenue increased from $1.6 million in Q1 2025 to $2.6 million in Q1 2026.
- Successful Launch of MYQORZO
- Commercial sales of MYQORZO began in late January 2026, marking a milestone for the company.
- Increasing Liquidity Position
- Cash equivalents and investments increased from $1.22 billion at year-end 2025 to $1.07 billion as of March 31, 2026.
- Managing Cash Utilization
- Net cash used in operations was $145.5 million for the quarter, up from $131.6 million in Q1 2025, reflecting continued investment in R&D.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Losses
- Operating expenses rose to $203 million in Q1 2026 from $157 million in Q1 2025, driven by increased marketing costs.
- Liquidity and Cash Flow Risks
- With ongoing losses, maintaining liquidity is a concern; cash utilized in operations reached $145.5 million.
- Patent Vulnerability
- Patent opposition proceedings in the EU could negatively impact commercial prospects for MYQORZO.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.67
What they said about what is next.
The company expects expenses will remain in the guidance range for R&D and SG&A at $830 million to $870 million for 2026.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Cytokinetics transitioned to a commercial biopharma company with FDA approval of MYQORZO in December 2025, China approval in December 2025 and European Commission approval in February 2026 for 5 mg, 10 mg, 15 mg and 20…
- 10-Q · November 5, 2025
- Cytokinetics reported Q3 2025 revenues of $1.936 million (up from $0.463 million in Q3 2024) but a substantially wider quarterly net loss of $306.178 million (vs. $160.545 million prior year), driving EPS to $(2.55).…
- 10-Q · August 7, 2025
- Cytokinetics reported Q2 revenue of $66.769M driven by a $64.353M license/milestone payment, lifting total six‑month revenue to $68.348M. Despite the one‑time revenue, the company recorded an operating loss of $111.506M…
- 10-Q · May 6, 2025
- Cytokinetics reported collaboration revenue of $1,579,000 for Q1 2025 (three months ended March 31, 2025), up from $835,000 in Q1 2024, but losses and cash burn widened. Operating loss was $155.6 million and net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CYTK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever